Corrections

Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1228 (Published 08 March 2017) Cite this as: BMJ 2017;356:j1228

The competing interest statement in this article by Neil Lineberry and colleagues was incomplete (BMJ 2016;355:i5078, doi:10.1136/bmj.i5078). As well as the reported links with MPIP, BM is a shareholder at GlaxoSmithKline, and serves as chair of MPIP; SG owns stock and stock options in Johnson and Johnson Common Stock; MB reports salary support from the American Medical Association, outside the submitted work; CK held stocks in AstraZeneca; CL is employed by the American College of Physicians as editor in chief of Annals of Internal Medicine, a medical journal that publishes clinical trials; and LC has received consulting or speaking fees outside the submitted work from Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, and Vanda, and has stock ownership in Bristol-Myers Squibb, Eli Lilly, J and J, Merck, and Pfizer.

View Abstract